5 listed sites: France (5) - 12 Mar `26Ritlecitinib with or without UVB light therapy

Ritlecitinib with or without UVB light therapy

Official title: Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo Prospective Multicentric Evaluator Blinded Interventional Study

Status: Recruiting now

Description:

Centre Hospitalier Universitaire de Nice plans to enroll about 56 participants. Ritlecitinib is an oral immune-modulating drug that blocks JAK3 and TEC-family signaling. Researchers hope it will reduce the immune attack on melanocytes and support repigmentation. Ritlecitinib is sold as Litfulo and is approved for severe alopecia areata in people age 12 and older; vitiligo would be a new use. Possible effects include headache, diarrhea, acne, and infections. People age 18 and older may qualify. The study is recruiting at 5 listed sites in France.

Start date: March 12, 2026

Completion date: June 01, 2029

Organizer: Centre Hospitalier Universitaire de Nice

Contact: Thierry Passeron, PhD

Tel.: +33 492 036 488

Email: passeron.t@chu-nice.fr

Link: https://clinicaltrials.gov/study/NCT07152626

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Ritlecitinib with or without UVB light therapy . By submitting you agree to our Privacy Policy.

FAQOther Questions